Evidence map›Paper›PMID 37695391›Full record

ReviewClinical and experimental medicine2023

LncRNA MALAT1 signaling pathway and clinical applications in overcome on cancers metastasis.

Madineh Mazarei, Venus Shahabi Rabori, Nazila Ghasemi, Mehrnaz Salehi, Najmeh Rayatpisheh, Negin Jahangiri, Mohammadreza Saberiyan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Madineh MazareiCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Venus Shahabi RaboriDepartment of Cardiology, Urmia University of Medical Sciences, Urmia, Iran.
Nazila GhasemiDepartment of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
Mehrnaz SalehiSchool of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Najmeh RayatpishehSchool of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Negin JahangiriDepartment of Biology, Faculty of Basic Sciences and Engineering, Gonbad Kavous University, Gonbad-e Kavus, Iran.
Mohammadreza SaberiyanDepartment of Medical Genetics, Faculty of Medicine, School of Medical Sciences, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. saberiyanmr@gmail.com.
Shahrekord University of Medical Sciences · IRGonbad Kavous University · IRHormozgan University of Medical Sciences · IRIslamic Azad University, Jahrom Branch · IRUrmia University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In spite of its high mortality rate and difficulty in finding a cure, scientific advancements have contributed to a reduction in cancer-related fatalities. Aberrant gene expression during carcinogenesis emphasizes the importance of targeting the signaling networks that control gene expression in cancer treatment. Long noncoding RNAs (lncRNAs), which are transcribed RNA molecules that play a role in gene expression regulation, are a recent innovative therapeutic approach for diagnosing and treating malignancies. MALAT1, a well-known lncRNA, functions in gene expression, RNA processing, and epigenetic control. High expression levels of MALAT1 are associated with several human disorders, including metastasis, invasion, autophagy, and proliferation of cancer cells. MALAT1 affects various signaling pathways and microRNAs (miRNAs), and this study aims to outline its functional roles in cancer metastasis and its interactions with cellular signaling pathways. Moreover, MALAT1 and its interactions with signaling pathways can be promising target for cancer treatment.

Indexed as

MicroRNAsNeoplasmsRNA, Long NoncodingCell Line, TumorCell ProliferationGene Expression RegulationGene Expression Regulation, NeoplasticHumansSignal TransductionMALAT1 long non-coding RNA, humanMicroRNAsRNA, Long NoncodingAngiogenesisChemoresistanceMicroRNAs (miRNAs)Notch signaling pathwayTargeting therapyWnt/β-catenin pathway

Identifiers

PMID37695391
OpenAlexW4386593006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.